<DOC>
	<DOC>NCT00903721</DOC>
	<brief_summary>The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.</brief_summary>
	<brief_title>Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis. Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate] Patients with a history of hypersensitivity to any ingredient of this drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>